1
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Condition(s):Breast Cancer; Triple Negative Breast Cancer; PD-L1 NegativeLast Updated:May 11, 2021Recruiting
TRODELVY: 9 Clinical Trials
Hide Studies Not Open or Pending
2
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 – MBC
Condition(s):Invasive Breast Cancer; Metastatic Breast Cancer; HR-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:May 10, 2021Recruiting
3
Sacituzumab Govitecan Plus EV in Metastatic UC
Condition(s):Urothelial Cancer; Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Bladder CancerLast Updated:April 20, 2021Not yet recruiting
4
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
Condition(s):Metastatic Urothelial CarcinomaLast Updated:May 10, 2021Recruiting
5
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Condition(s):HRD Cancer; SCLC; Advanced Solid TumorsLast Updated:May 14, 2021Not yet recruiting
6
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Condition(s):HER2-negative Breast Cancer; Triple Negative Breast CancerLast Updated:December 14, 2020Recruiting
7
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- MBC
Condition(s):Metastatic Breast CancerLast Updated:February 25, 2021Recruiting
8
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
Condition(s):Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8Last Updated:May 13, 2021Recruiting
9
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer Triple-Negative Breast Cancer
Condition(s):Breast CancerLast Updated:April 30, 2021Completed